A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Patients With a History of Being Poorly Compliant With Taking Their Medication - Article Caverject; Edex Kit
Clinical Trial: A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Patients With a History of Being Poorly Compliant With Taking Their Medication
This study is not yet open for patient recruitment.
Verified by Janssen-Ortho Inc., Canada November 2005
|Schizophrenia || Drug: risperidone ||Phase IV |
MedlinePlus related topics: Schizophrenia
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Pragmatic Randomized Trial of Risperdal® CONSTA® (Risperidone) Versus Oral Atypical Antipsychotics in Poorly Adherent Subjects With Schizophrenia in a Routine Care Setting.
Secondary Outcomes: PANSS, CGI-S and CGI-C, RUQ, AQoL, PSP, evaluation of symptomatic remission over time, proportion of clinical intensification of symptoms during the trial, time to intensification of symptoms and the number of incidences of intensification of symptoms
Expected Total Enrollment: 260
This is a randomized, open-label, parallel group, multi-country and multi-centre study of Risperdal long-acting formulation versus oral atypical antipsychotics in subjects with a DSM-IV TR diagnosis of schizophrenia currently being treated with oral antipsychotic medication. The primary objective of this trial is to determine whether Risperdal long-acting formulation provides improved effectiveness over a 2-year period, measured by the proportion of subjects who experience a clinical exacerbation, as compared to oral atypical antipsychotics prescribed in a routine care setting for the treatment of subjects with schizophrenia. Subjects will be randomized to an oral atypical antipsychotic (risperidone, olanzapine, quetiapine, and where commercially available, aripiprazole and amisulpride) or to Risperdal long-acting formulation. For Risperdal long-acting formulation subjects, study medication will be administered by intramuscular injection every 2 weeks at doses of 25, 37.5 or 50 mg. Oral supplementation with the current oral atypical antipsychotic or conventional neuroleptic is required for the first 3 weeks following the initial injection and dose increases. Dose increases can be made as per product labeling. The primary measure of effectiveness is the reduction in the proportion of subjects experiencing a clinical exacerbation after being in the study for 3 months. Additional measures of effectiveness include: symptom improvement on the Positive and Negative Syndrome Scale for schizophrenia (PANSS) and Clinical Global Impression (CGI) - S/C; use of health care resources as assessed by Resource Utilization Questionnaire (RUQ) and changes in quality of life, assessed using Assessment of Quality of Life (AQoL) questionnaire; time to first clinical exacerbation; the number of clinical exacerbations calculated at 2 time points: occurring 12 weeks post-randomization and the entire trial duration; the proportion of clinical exacerbations for the entire trial period; the evaluation of symptomatic remission over time; and the Personal and Social Performance Scale (PSP). Safety assessments include the incidence of adverse events throughout the study, AIMS, laboratory tests, vital signs, weight, waist and hip circumference and physical examination.
Oral atypical antipsychotic (risperidone, olanzapine, quetiapine, aripiprazole or amisulpride, dosage according to product labeling) or risperidone, long-acting formulation (25, 37.5 or 50 mg) administered by intramuscular injection every 2 weeks, for the 2-year study. Oral supplementation with the current oral atypical antipsychotic or conventional neuroleptic is required for the first 3 weeks following the initial injection and dose increases.
Inclusion Criteria: - Diagnosis of schizophrenia as per DSM-IV - have had at least 2 hospitalizations or 2 clinical worsening of symptoms over the past 2 years due the patient suspected of being poorly compliant with taking their medication - is currently receiving treatment with an antipsychotic per local labeling, and has a history in the last 5 years of a satisfactory response (minimum of 6 weeks) to oral antipsychotics (excluding clozapine) - otherwise healthy, as confirmed by physical exam, vital signs, and laboratory testing: female subjects must be surgically sterile, or practicing an effective method of birth control before entry and throughout the study, and have a negative urine pregnancy test at screening before study entry
Exclusion Criteria: - Subjects with a primary DSM-IV TR Axis I diagnosis other than schizophrenia - previously treated or currently on clozapine - have a serious, unstable and untreated medical illnesses, such as vascular or cardiovascular disease, history of liver or kidney disease, significant cardiac, pulmonary, gastrointestinal, endocrine, neurological or metabolic disturbances - at significant risk of suicide or violence at study start - evidence of alcohol or medication abuse or dependence.
Location and Contact Information
Janssen-Ortho, Canada Clinical Trial, Study Director, Janssen-Ortho Inc., Canada
Last Updated: December 2, 2005
Record first received: November 18, 2005
ClinicalTrials.gov Identifier: NCT00256997
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2006-01-10